Roles
- Assistant Professor of Clinical Medicine
-
Biography
Sangeetha Venugopal, M.D., is a board-certified hematologist who trained at renowned institutions, including Montefiore Medical Center and the Icahn School of Medicine at Mount Sinai in New York, and completed an additional leukemia-focused fellowship at the UT MD Anderson Cancer Center in Houston, Texas.
A well-published clinician-investigator, Dr. Venugopal focuses research on improving treatment outcomes for patients with myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN), through clinical trials, translational investigations, and precision medicine approaches. Dr. [Name] has a particular interest in identifying novel targeted therapies, elucidating mechanisms of treatment resistance, and developing strategies to eradicate measurable residual disease in AML. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Genetic Mutations Accumulate in Smokers with Myelodysplastic Syndromes and Worsen Outcomes
The Latest Treatment Options for Acute Myeloid Leukemia
Mentoring the Next Generation in Blood Cancer Research
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 7 clinical trials.
-
To determine the response rate of olutasidenib monotherapy in patients with IDH1-mutated CCUS or lower-risk MDS/CMMLTo evaluate the rates of transfusion independence, defined as the absence of transfusions over a period of at least 8 weeksTo ascertain the safety and tolerability of olutasidenib monotherapy in these patient populationsTo determine survival and rates of leukemia transformationTo analyze reduction in IDH1 clone size
- Principal Investigator: Sangeetha Venugopal
- Study Phase: Phase II
- Enrollment Status: Open
-
This study tests different doses of the drug to target 1 in 5 patients to experience a severe or life-threatening side effect. This drug in combination with daunorubicin and cytarabine has not been tested in people. This study tests different doses of the drug to test the safety of the drug. There will be between 38 and 46 people taking part in this study.Daunorubicin and cytarabine have already been approved by the FDA to treat newly diagnosed therapy related acute myeloid leukemia.
- Principal Investigator: Sangeetha Venugopal
- Study Phase: Phase I
- Enrollment Status: Open
-
The purpose of this portion of the study is to evaluate the safety of and how you tolerate the study drugs (ASTX030 and venetoclax) when taken together, any potential benefits of taking the study drugs together, and the potential interaction between ASTX030 and venetoclax compared to SC (injectable) azacitidine and venetoclax. The study drugs being tested as a combination in this study, ASTX030 (azacitidine and cedazuridine) and venetoclax, are investigational and have not been approved to treat AML.
- Principal Investigator: Sangeetha Venugopal
- Study Phase: Phase III
- Enrollment Status: Open
-
This study is being done to test if the study drug (momelotinib) works to improve anemia, a condition associated with myelodysplastic syndrome (MDS), makes you feel better, is safe, well-tolerated and what dose of the drug works best.
- Principal Investigator: Sangeetha Venugopal
- Study Phase: Phase II
- Enrollment Status: Open
-
Dose Escalation: To assess the safety and tolerability of DISC-0974 following repeated SC doses in participants with primary MF, post-ET MF, or post-PV MF (collectively referred to as MF) and anemiaExpansion: To characterize the effects of DISC-0974 on anemia response at the recommended Phase 2 dose (RP2D) in MF and anemia
- Principal Investigator: Sangeetha Venugopal
- Study Phase: Phase I/II
- Enrollment Status: Open
-
The purpose of this study is to test how safe and tolerable the study drug M3814 at different doses in combination with the usual drugs, mitoxantrone, etoposide, and cytarabine. Dose” is defined as the amount of drug you get, such as 100 mg.
- Principal Investigator: Sangeetha Venugopal
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
The purpose of this study is to learn about the safety, tolerability and efficacy (how well a drug works) of iadademstat in combination with gilteritinib for the treatment of R/R AML with FLT3 mut+.
- Principal Investigator: Sangeetha Venugopal
- Study Phase: Phase I
- Enrollment Status: Not Accepting